Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 6/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183545 | 0.81 | KMT2A (0.66) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| SCHEMBL7206975 | 0.80 | KMT2A (0.62) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| SCHEMBL5807014 | 0.79 | KMT2A (0.63) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| Ammonia Solution, Strong SCHEMBL27671164 | 0.79 | KMT2A (0.63) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| SCHEMBL258449 | 0.79 | TDP1 (0.63) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| SCHEMBL5807015 | 0.79 | TDP1 (0.63) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| SCHEMBL15200988 | 0.77 | LMNA (0.58) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| Nifuroxime SCHEMBL465512 | 0.76 | LMNA (0.76) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| Nifuroxime SCHEMBL5025023 | 0.76 | LMNA (0.76) | KMT2ATDP1L3MBTL1MEN1LMNA | |
| Nitric Acid SCHEMBL11753070 | 0.76 | KMT2A (0.59) | KMT2ATDP1L3MBTL1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | claimed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | claimed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | claimed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | claimed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | claimed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
| US-5119221-A | Containing polymer adjustment layer | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| EP-0351718-A1 | Liquid crystal display device comprising improved alignment layers for liquid crystal | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1990-01-24 | — | — | EP | disclosed |
| US-4243596-A | USED IN PRODUCTION OF BACTERICIDES | REKTORAT SLOVENSKEJ VYSOKEJ SKOLY TECHNICKEJ (CS) | 1981-01-06 | — | — | US | disclosed |
| US-4243596-A | USED IN PRODUCTION OF BACTERICIDES | REKTORAT SLOVENSKEJ VYSOKEJ SKOLY TECHNICKEJ (CS) | 1981-01-06 | — | — | US | disclosed |
| US-3993643-A | ANTISCHISTOSOMAL | STANFORD RESEARCH INSTITUTE (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | KMT2A 1722/4885TDP1 3290/4885L3MBTL1 3535/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | KMT2A 1722/4885TDP1 3290/4885L3MBTL1 3535/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | KMT2A 1722/4885TDP1 3290/4885L3MBTL1 3535/4885 |
| US-20020151544-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | KMT2A 1722/4885TDP1 3290/4885L3MBTL1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.